Eli Lilly vs Novartis

Eli Lilly (LLY), health care, and Novartis (NVS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Eli Lilly is worth $1.26T on the stock market and Novartis $301.5B: Eli Lilly is valued at 4.2 times as much. Eli Lilly trades at 45.9 times earnings and Novartis at 30.5. Over the past year Eli Lilly's share price has moved +39.0% and Novartis's +25.1%.

Key facts

Eli Lilly market value
$1.26T
Novartis market value
$301.5B
Eli Lilly P/E
45.9
Novartis P/E
30.5
Eli Lilly revenue
$65.2BFY to 2025-12-31
Novartis revenue
$54.5BFY to 2025-12-31
Superinvestors holding both
8

Market values as of .

Eli Lilly vs Novartis: every measure side by side
Measure Eli Lilly Novartis
SectorHealth CareHealth Care
Country United States Switzerland
Fiscal year ends2025-12-312025-12-31
Size
Market cap$1.26Thigher$301.5Blower
Revenue$65.2Bhigher$54.5Blower
Earnings$20.6Bhigher$14Blower
Employees50,000lower75,267higher
Total assets$112.5Bhigher$110.9Blower
Valuation
P/E45.9higher30.5lower
P/S19.3higher5.5lower
P/B31.3—
Dividend yield0.47%—
Profitability
Operating margin—32.4%
Balance sheet
Net assets$26.5Blower$46.1Bhigher
Total liabilities$85.9Bhigher$64.4Blower
Total debt$42.5Bhigher$28.7Blower
Cash on hand$7.3Blower$11.4Bhigher
Price change
Today-1.22%lower-0.35%higher
1 year+39.0%higher+25.1%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Eli Lilly / Novartis). Who owns LLY · Who owns NVS

Further comparisons

Learn

Questions and answers

Which is bigger, Eli Lilly or Novartis?

By market value, Eli Lilly is the larger: $1.26T against $301.5B for Novartis. By revenue in its latest fiscal year, Eli Lilly is the larger: $65.2B against $54.5B for Novartis.

Which has the higher P/E ratio?

Eli Lilly: 45.9, against 30.5 for Novartis. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has more debt?

Eli Lilly: $42.5B, against $28.7B for Novartis. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Eli Lilly and Novartis?

In their latest 13F filings, Primecap team, Jeremy Grantham (co-founder), Ken Fisher, Rajiv Jain, Larry Robbins, Brandon Haley, Murray Stahl and Dodge & Cox team hold both.

Cite this page

Funkfolio, “Eli Lilly vs Novartis”, data as of 17 November 2026. https://funkfolio.com/compare/lly-vs-nvs

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.